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Abstract
Background: Cerebrotendinous xanthomatosis (CTX) is a rare lipid-storage disease. Neuromuscular abnormality and
autonomic system (ANS) dysfuction in CTX are rarely examined in large-scale studies in the literature. We studied
the peripheral nervous system, myopathology, and autonomic system of four CTX patients and performed a
literature review of the reported CTX patients with peripheral neuropathy.
Methods: Four biochemically and genetically confirmed CTX patients, belonging to two families, were included for
study and all received nerve conduction study (NCS), muscle biopsy for histopathologic and ultrastructural study,
skin biopsy for intraepidermal nerve fiber (INEF) density measurement, autonomic testings including sympathetic
skin response, R-R interval variation and head-up tilt test using an automated tilt table to record the changes of
blood pressure and heart rate in different postures. The Q-Sweat test was also applied for the detection of sweat
amount and onset time of response. The clinical characteristics, study methods and results of 13 studies of
peripheral neuropathy in CTX patients in the literature were also recorded for analysis.
Results: The results of NCS study showed axonal sensory-motor polyneuropathy in three CTX cases and mixed
axonal and demyelinating sensor-motor polyneuropathy in one. The myopathological and histopathologic studies
revealed mild denervation characteristics, but the ultrastructural study revealed changes of mitochondria and the
membranous system, and increased amounts of glycogen, lipofuscin and lipid deposition. The ANS study revealed
different degrees of abnormalities in the applied tests and the INEF density measurement showed small fiber
neuropathy in three of the four CTX patients. The literature review of peripheral neuropathy in CTX revealed
different types of peripheral neuropathy, of which axonal peripheral neuropathy was the most common.
Conclusions: Peripheral neuropathy, especially the subtype of axonal sensori-motor neuropathy, is common in patients
with CTX. Evidence of lipid metabolic derangement in CTX can be reflected in ultrastructural studies of muscles. With an
adequate multi-parametric evaluation, a high incidence of ANS abnormalities can be seen in this rare lipid-storage disease,
and a high incidence of small fiber involvement is also reflected in the IENF density measurement of skin biopsies.
Background
Cerebrotendinous xanthomatosis (CTX), a rare autoso-
mal recessive cholestanol lipidosis, is caused by a defi-
ciency of the gene encoding the mitochondrial sterol
27-hydroxylase (CYP27A1) [1-4] and subsequently
results in an abnormal deposition of cholestanol and
cholesterol in various organs. The major clinical presen-
tations of CTX are juvenile cataracts, tendinous xantho-
matosis and various neurological symptoms including
dementia, pyramidal signs and cerebellar ataxia [1-4].
There have been case reports and small-scale studies on
peripheral neuropathy in CTX using different measuring
methods [5-17]. However, the state of the autonomic
nervous system (ANS) [14,16] and myopathologic fea-
tures [15,18] in CTX have rarely been reported, and dif-
ferent results have been noted among these limited
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studies. In this study, we reported the abnormalities of
neuromuscular and ANS systems of four CTX patients




The clinical data of the four included CTX cases are
listed in Table 1. All four cases (Cases I-1, I-2, II-1 and
II-2) had an elevation of serum cholestanol at presenta-
tion, with initial levels ranging from 24.7 to 46.8 ug/ml
(mean = 34.3 ug/ml, normal value = 3.37 ± 1.55 ug/ml).
The diagnosis of CTX was made in 1991 in Family I,
and 2004 in Family II. The clinical and neuroimaging
features, and results of biochemical and genetic studies
of these four CTX cases have been previously reported
[19-21]. All four cases received chenodeoxycholic acid
(CDCA) treatment (750 mg/day) from the time of diag-
nosis. There were three CTX siblings in Family I, how-
ever one died before this study, and therefore only two
were included in this study. This retrospective study
was approved by the ethics committee of Chang Gung
Memorial Hospital (IRB 99-3615B). Cases I-1 and I-2
(Family 1) and Cases II-1 and II-2 (Family II) have con-
sented to publication of their clinical, laboratory and
genetic data on March 30, 2006 and October 12, 2004,
respectively.
Nerve conduction study and electromyography study
Nerve conduction studies (NCS) studies were performed
using a VikingSelect system (Nicolet Biomedical Inc.
Madison, USA). All testing was done in the same room
and with the same temperature conditions, and the skin
temperature was kept ≧32°C. The studied nerves
included sural, tibial, peroneal, superficial radial, medial
plantar, median and ulnar nerves. Amplitudes of the
sensory action potential and compound muscle action
potential as well as nerve conduction velocity, F wave
response, distal latency and soleus-H reflex were
recorded. In this study, the referential data for Chinese
were cited from the report of Lin et al. [22]. In electro-
myographic (EMG) studies, the proximal and distal
muscles of the upper and lower limbs were sampled.
Muscle biopsies
Muscle biopsies from the vastus lateralis of quadriceps
were obtained with a BergstroÈm needle in all four
CTX cases. Both histopathological and ultrastructural
studies were processed according to standard proctocols
[23-25]. The specimens processed for light microscopic
investigations, were stained with haematoxylin/phloxine,
ATPase, succinate dehydrogenase, cytochrome oxidase,
Sudan black, periodic acid-Schiff and acid phosphatase.
All muscle specimens were also prepared for ultrastruc-
tural examinations.
Table 1 Clinical data of the four cerebrotendinous xanthomatosis (CTX) patients
Family I II
Case No 1 2 1 2
Gender F M M M
Age (years) 54 50 31 29
Age at CTX diagnosis (years) 37 32 24 23
Disease duration at neuromuscular study (years) 49 45 21 17
Body height (cm) 143 155 164 175
Body weight (kg) 45 50 74 114
Genetic mutation (CYP 27 gene) Homozygous: 305delC (exon 2) Heterozygous: 1333C > T (exon 8) and IVS 7+1G > A (intron 7)
Clinical manifestation
Tendinous xanthomatosis + + + +
Cataracts + + + +
Osteoporosis with multiple fractures + + - -
Mental retardation + + + +
Cerebellar sign + + + +
Pyramidal sign + + + +
Parkinsonism + + - -
Glove-stock paresthesia - - - -
Hyporefelxia - - - -
Distal foot muscle atrophy - - - -
Posture related problems - - - -
Sphincter problems - - - -
Sweating problems - - - -
No = number; + = present; - = absent; F = female; M = male
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Skin biopsies and quantitation of skin innervation
A punch skin biopsy of 3-mm in diameter was taken
from the right distal leg 10 cm proximal to the lateral
malleolus under local anesthesia with 2% lidocaine fol-
lowing the established protocol [26]. The sampled skin
tissue was fixed in paraformaldehyde overnight. Sections
50 μm perpendicular to the dermis were immunostained
with antiserum to protein gene product 9.5 (PGP 9.5, 1:
1000; UltraClone, Isle of Wight, UK) and the reaction
product was demonstrated using chromogen SG (Vector
Laboratories).
Epidermal innervation was quantified according to
established criteria in a coded fashion [27]. The obser-
vers were blinded to the clinical information. PGP 9.5
(+) nerves in the epidermis of each skin section were
counted at a magnification of 40× with a BX40 micro-
scope (Olympus, Tokyo, Japan). The length of the epi-
dermis along the upper margin of the stratum corneum
in each skin section was measured with ImageJ version
1.43 software (Image Processing and Analysis in Java,
National Institutes of Health, Bethesda, MD: http://
rsbweb.nih.gov/ij/download.html). The intraepidermal
nerve fiber (IENF) density was expressed as the number
of fibers/mm of epidermal length. In the distal leg, nor-
mative values (mean ± SD, 5th percentile) of IENF are
11.16 ± 3.70 (5.88) fibers/mm for subjects aged < 60
years and 7.64 ± 3.08 (2.50) fibers/mm for subjects aged
≧ 60 years, and age- and gender-matched controls were
retrieved from the previously described database [28].
Autonomic function assessments
Sympathetic skin response (SSR) and R-R interval varia-
tion (RRIV) were performed using a VikingSelect system
(Nicolet Biomedical Inc. Madison, USA). RRIV is
defined as heart rate (HR) variability in deep breathing
test (patients are asked to breath at a rate of 6 breaths/
min ) as maximus HR -minimus HR/mean HR, and it is
used to measure the cardiac parasympathetic activity
[29]. Head-up tilt (HUT) tests for orthostatic blood
pressure (BP) and heart rate (HR) changes were per-
formed on an automated tilt table. Patients were first
placed in a supine position and then tilted to 70 degrees.
Data recorded using a continuous monitor (Finapres BP
monitor 2300, Finameter Pro, Ohmeda; Englewood, OH,
USA) included systolic, diastolic, and mean BP continu-
ously in serial recordings at 0, 1, 2, 3, and 5 minutes
after tilting up, and at the third minute after lying back.
In this study, “orthostatic hypotension” was defined as a
reduction in a systolic BP of ≧ 20 mmHg or a diastolic
BP of ≧ 10 mmHg within three minutes of upright tilt
to an angle of ≧ 60° or standing. We used a “30:15
ratio” which may denote the cardiac parasympathetic
activity [30], to assess this physiological response by
measuring the ratio of the RR interval at beat 30 while
standing to the RR interval at beat 15. The slope of the
regression line between the R-R interval and systolic BP
values was computed for each sequence, and taken as a
measurement of baroreflex sensitivity (BRS, ms/mmHg)
which may measure both sympathetic and parasympa-
thetic activities [31] in this HUT study [32].
Q-Sweat recordings
The Q-Sweat recording was performed at the same room
temperature (21-23°C), room humidity (56-58%) and skin
temperatures over the tested sites (> 34°C). All four CTX
cases underwent left limb Q-Sweat recordings using the
standard regional sites (forearm, proximal leg, distal leg,
and foot) with a Q-Sweat device (WR Medical Electro-
nics Co, Stillwater, Minnesota, USA) by the evoke of
acetylcholine solution (10% w/v). Sweat amount and
onset time of response were displayed using TestWorks
software (WR Medical Electronics Co., Stillwater, Minne-
sota) [33]. In addition, 90 sex- and age-matched healthy
subjects from the normative database acted as control for
this test. The human ethics committee of Chang Gung
Memorial Hospital approved the study (IRB98-0805B).
Reported CTX patients with peripheral neuropathy in the
literature
For a better delineation of peripheral neuropathy fea-
tures in CTX patients, the clinical data and described
types of peripheral neuropathy reported in the literature
[5-17] were included for analysis.
Results
NCS and EMG
The results of the NCS study of the four CTX cases
showed a mild axonal sensory-motor polyneuropathy
characterized by a decreased amplitude in sensory and
motor nerves, and an absent response in the sural nerves
in Cases I-1, I-2 and II-2, and mixed axonal and demyeli-
nating sensory-motor polyneuropathy characterized by
slowed nerve conduction velocity, prolonged F response
and absent response in sural nerves in Case II-1 (Table 2).
In EMG studies, only denervation changes characterized
by decreased recruitment patterns and increased polypha-
sic waves in the distal muscles were detected.
Muscle biopsies
In light microscopic examination, no histopathologic
features suggesting myopathic change were noted, but
small grouping denoting slight neurogenic changes was
observed. The findings of the ultrastructural study are
listed in Table 3 and demonstrated in Figure 1.
Quantitation of skin innervations
The IENF densities were as follows: 3.19 fibers/mm in
Case I-1, 6.14 fibers/mm in Case I-2, 5.45 fibers/mm in
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Case II-1 and 5.13 fibers/mm in Case II-2. This result
showed a decrease of IENF in Cases I-1, II-1 and II-2.
Results of autonomic testings (Table 4)
In RRIV measurement, decreased value was found in
Case I-1. In SSR measurement, no abnormal responses
were detected on either the soles or palms of these four
cases. The results of the HUT test showed: 1) no abnor-
mal orthostatic HR or BP changes in all four cases; 2)
abnormally decreased values in Cases I-1 and I-2 in the
measurement of the “30:15 ratio"; and 3) negative and
decreased values in Cases I-1 and I-2 in BRS
measurement.
In the Q-Sweat test, compared with the data of nor-
mal control (Table 4), sweat output showed a reduc-
tion of sweat volume only in the forearm and foot of
Case II-1. With a relative comparison, the sweat
volumes were as follows: foot sweat volume < 1/3 of
the forearm value in Case I-1; foot and proximal leg <
1/3 of the forearm value in Case I-2; and forearm and
foot volume < 1/3 of the proximal leg value in Case
II-1.
Table 2 Nerve conduction study findings of the four cerebrotendinous xanthomatosis patients
Case Median Ulnar Superficial
radial
Peroneal Tibial Sural H-reflex (N
< 27.6)
Motor Sensory Motor Sensory
I-1 R DL (ms) 4.4 (N < 3.6) 2.8 2.9 (N < 2.8) 2.2 1.9 4.0 (N < 4.2) 2.7 (N < 4.9) Absent 31.0
L DL (ms) 4.4 3.0 2.5 2.9 1.7 4.0 3.7 Absent 30.4
R CV (m/s) 50 (N > 57.8) 50 (N > 51.7) 50 (N > 61.4) 56 (N > 56.3) 63 (N > 50) 39 (N > 48.6) 45(N > 50.5) Absent
(N > 47.4)
L CV (m/s) 49 47 54 49 71 42 40 Absent
R Amp 7.6 (N > 11.9) 47 (N > 33) 11 (N > 11.7) 32 (N > 26.1) 23 (N > 15) 4.1 (N > 6.0) 5.5 (N > 13.1) Absent
(N > 12.5)
L Amp 7.1 21 8.1 38 33 4.5 9.6 Absent








L F waves 27.9-0.8 26.4-1.0 47.4-0.4 50.4-0.8
I-2 R DL (ms) 4.4 2.7 3.2 2.6 2.1 4.2 5.0 Absent 32.4
L DL (ms) 4.0 2.8 3.0 2.2 1.8 3.9 3.3 Absent 32.6
R CV (m/s) 49 53 54 46 57 39 41 Absent
L CV (m/s) 51 50 51 54 67 41 40 Absent
R Amp 8.6 23 7.3 26 34 2.9 10.5 Absent
L Amp 9.2 31 8.8 13 60 3.8 6.7 Absent
R F waves 30.0-0.5 28.8-1.0 50.5-1.0 51.8-1.0
L F waves 28.3-1.0 28.4-1.0 50.1-0.6 53.9-1.0
II-1 R DL (ms) 4.3 2.8 3.0 2.4 2.1 Absent 4.5 Absent 38.4
L DL (ms) 4.1 3.0 2.8 2.5 2.0 4.9 5.1 Absent 37.5
R CV (m/s) 44 50 42 50 56 Absent 32 Absent
L CV (m/s) 46 47 43 48 60 30 34 Absent
R Amp 10.3 42 11.5 20 25 Absent 4.0 Absent
L Amp 11.7 47 9.9 29 32 2.4 2.6 Absent
R F waves 32.6-1.0 32.1-1.0 Absent 70.6-0.6
L F waves 30.4-0.9 30.4-1.0 79.2-0.2 75.7-0.9
II-2 R DL (ms) 4.0 2.5 2.8 2.0 1.7 4.4 3.4 Absent 31.9
L DL (ms) 4.2 2.7 3.0 2.3 1.7 3.8 3.8 Absent 31.6
R CV (m/s) 52 56 58 60 71 39 41 Absent
L CV (m/s) 52 52 50 53 71 43 39 Absent
R Amp 8.5 29 6.6 38 16 3.2 4.7 Absent
L Amp 7.4 50 6.7 40 29 4.7 2.0 Absent
R F waves 29.8-1.0 30.4-0.8 54.2-0.3 53.3-1.0
L F waves 29.6-1.0 31.6-0.9 50.9-0.8 56.5-0.9
N = normal; DL = distal latency; CV = conduction velocity; Amp = amplitude (mV in motor nerves and μV in sensory nerves); F waves = minimal latency-
persistent rate; H-reflex = soleus H-reflex in minimal latency; AT = anterior tibialis; FDI = 1st dorsal interosseous muscle; R = right; L = left
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Reported CTX patients with peripheral neuropathy:
summary of clinical features (Table 5)
In the literature review, we found 13 reports [5-17] that
had studied peripheral neuropathy of CTX patients. The




CTX is an uncommon lipid storage disease, and its asso-
ciated neuromuscular abnormalities have rarely been
examined in large-scale studies. The reported CTX
cases with peripheral neuropathy [5-17] used different
measurement methods (NCS and/or EMG and/or sural
nerve biopsy and/or muscle biopsy) for assessment and
confirmation, and also listed differently-described types
of peripheral neuropathy (Table 5). Because of these dif-
ferences in clinical evaluation and study results, a matter
of debate in the pathologic findings and etiologies of
peripheral neuropathy in CTX were also elicited among
these reports [5-17]. Mondelli et al. [13], used electro-
physiologic studies including NCS, and they found that
eight CTX patients had a moderate sensori-motor neu-
ropathy of demyelinating type, but this finding was not
further confirmed by pathological study of nerve. Argov
et al. [9] also noted a demyelinating process in a study
of peripheral neuropathy in three CTX patients. In
another study by Verrips et al. [15] using NCS and
EMG studies, seven of their included CTX cases had a
peripheral neuropathy (five with axonal type, one with
mixed axonal and demyelinating type, and one unspeci-
fied), two a normal study and one with myopathic
findings. In our study, different degrees of axonal sen-
sory-motor polyneuropathy in three cases and mixed
axonal and demyelinating sensori-motor polyneuropathy
in one case were found, and their myo-histopathologic
features also reflected this neuropathic process showing
denervation features. Our study results are consistent
with those of Verrips et al. [15] in that axonal degenera-
tion was concluded to be the predominant process of
neuropathy in CTX, although in some of their patients,
features of chronic demyelination and remyelination
were also found [15]. In pathologic studies of peripheral
nerves, Voiculescu et al. [10], Donaghy et al. [11] and
Wang et al. [17] found the deposition of lipid in
Schwann cells in CTX patients with neuropathy, while
this pathologic change was not noted in the studies of
Katz et al. [8], Argov et al. [9] and Verrips A et al.,
[15]. Besides our four cases, another 12 CTX patients
[15-17] with a peripheral neuropathy had a genetic ana-
lysis, but different mutation patterns were noted. This
lack of correlation between the genotype and pathogen-
esis of peripheral neuropathy or other phenotypes was
noted in the studies of Verrips et al. [15,34].
Muscle Abnormality
In the myopathologic study, mild neurogenic change
was the main finding of our four CTX cases, and this
denervation feature was also found in other related
reports of CTX patients with peripheral neuropathy
[7,10,15,18]. In the ultrastructual study of muscles, the
main abnormal findings included changes of the mito-
chondria and membranous system, and an increased
amount of lipid droplets, lipofuscin and glycogen (Table
3). These ultrastructual findings are consistent with
those reported by Verrips et al. [15] and Federico et al.
[18]. Based on these ultrastructural changes, Federico et
al. [18] concluded that: the primary alteration of lipid
metabolism in CTX might lead to an impairment of the
energy processes of muscle and subsequent mitochon-
drial morphological change. However, all these ultra-
structural changes are nonspecific for CTX and can be
found in other muscle disorders or can even be a nor-
mal constituent of human skeletal muscles [15,24,25].
Compared with the nervous system, muscles are not a
preferable site for cholestanol deposition [35], but all
these ultrastructural changes can be attributed to an
abnormal metabolic state in CTX which is reflected by
the abnormality of the membrane system and abnormal
deposition of lipid droplets, lipofuscion and glycogen as
shown in this study.
ANS Abnormality
In the literature, the state of ANS in CTX has only been
described in two case reports [14,16]. In the report of
Geraldes et al. [16], no involvement of the ANS in a
Table 3 Ultrastructural features of myopathology of the
four cerebrotendinous xanthomatosis patients





change in size and shape ++
+
++ ++ +
increase in amount ++
+
++ ++ +
Changes of membranous system
triads proliferation, swollen - ++ + -













Increased amount of lipofuscin + + + ++
Increased amount of glycogen ++ ++ + ++
+ = positive; - = negative; the number of “+” = different amounts
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CTX case with severe neuropathy was found. However
in the report of Arpa et al. [14], an opposite result was
found, showing a postganglionic cholinergic failure in a
CTX patient with somatic peripheral neuropathy. In this
study, we arranged multiparametric evaluation (SSR,
RRIV, HUT study for orthostatic BP and HR recording,
and Q-Sweat recording) to assess the functional state of
ANS of the four CTX patients. The evaluation results
revealed different degrees of laboratory evidence of ANS
abnormalities in three of the four CTX patients, in
which both sympathetic and parasympathetic systems
were involved (Table 4). Despite these different degrees
of laboratory abnormalities were demonstrated, they
were not reflected fully in clinical blood pressure and
heart rate changes in these four cases. In the meanwhile,
there was also a mismatch in the inter-lab data such as
the finding of SSR and Q-Sweat test. These mismatches
need further verification by large-scale study.
This ANS abnormality can be partially reflected patholo-
gically by the findings of skin biopsy IENF measurement,
which is a reliable tool with high diagnostic specificity and
good sensitivity for small fiber disease [36-38]. In a study
conducted by Schuller et al. [39], a comparison of the
three small fiber systems revealed that functionally differ-
ent systems were damaged independently, and isolated
affection of each fiber type was frequently observed. There-
fore, biopsy results must be interpreted in conjunction
with neurologic findings and laboratory results, including
Figure 1 
   
a                     b                     c  
   
d                     e                     f 
   
g                     h                     i 
Figure 1 Summarized muscle ultrastructural findings of the four cerebrotendinous xanthomatosis cases. 1a. subsacrolemmal
accumulation of mitochondria (arrow), (bar = 1 μm); 1b. mitochondria change in shape and enlarged in size (arrow), (bar = 1 μm); 1c. increased
amount of lipid droplets (arrow), (bar = 2 μm); 1d. lipofuscin (arrow), (bar = 1 μm); 1e. triads proliferation (arrow), (bar = 1 μm); 1f. swollen
sacroplasmic reticulum (arrow), (bar = 1 μm); 1g. laminated bodies (arrow), (bar = 0.5 μm); 1 h. membranous-like debris (arrow) in the
subsacrolemmal space, (bar = 1 μm); 1i. increased amount of glycogen (marked as G, bar = 0.5 μm).
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Table 4 Autonomic findings
I-1 I-2 II-1 II-2
RRIV (%) (N > 15) 3.53 15.7 24.2 25.4
Head-up tilt test NR NR NR NR
BR sensitivity (msec/mmHg) -1.9 -1.4 2.3 0.7
30:15 ratio (N > 1.03) 1.03 0.95 1.11 1.37
SSR
onset latency (ms) R palm 1320 1700 1440 1720
L palm 1400 1700 1400 1770
R sole 2300 2280 2060 2280
L sole 2290 2280 2250 2280
amplitude (μV) R palm 2652 1569 978 1314
L palm 2198 921 869 1099
R sole 315 159 61 688
L sole 399 239 74 562
Q-Sweat test
onset latency (seconds) Forearm 137 219 185 275
Proximal leg 217 194 165 128
Distal leg 165 148 168 136
Foot 165 203 189 122
total volume (μl) Forearm 0.150 0.298 0.015 0.450
Proximal leg 0.134 0.063 0.199 1.283
Distal leg 0.183 0.108 0.294 1.409
Foot 0.029 0.095 0.030 0.700
skin temperature (°C) Forearm 36.5 36.4 36.5 35.4
Proximal leg 35 35.8 36.4 35.7
Distal leg 35.6 36.3 34.9 35.3
Foot 35.7 35.2 34.7 35.4
room temperature (°C) 23 21 21 21
room humidity (%) 56 57 58 58
RRIV: R-R interval variation; NR: normal blood pressure (BP) and heart rate (HR) response in head-up tilt test: no abnormal change in BP and HR; N: normal; SSR:
sympathetic skin response; Q-Sweat: quantitative sweat measurement.
In Q-Sweat test, the total sweat volume (median (min, max) for female normal control were 0.495 (0.02, 3.814) (forearm), 0.505 (0.06, 4.49) (proximal leg), 0.389
(0.015, 4.914) (distal leg) and 0.203 (0.014, 0.802) (foot), and for male normal control were 1.079 (0.02, 3.814) (forearm), 1.091 (0.029, 2.734) (proximal leg), 1.107
(0.043, 2.902) (distal leg) and 0.585 (0.041, 1.718) (foot).




Total case No/gene mutation/ age or
range of age (y/r)






[5]/ 1079 4/ND/12-27 S-M pnp D ND ND
[6]/1979 1/ND/25 ND D D ND
[7]/1984 4/ND/35-43 S-M pnp D D D
[8]/1985 1/ND/50 S-M pnp D D ND
[9]/1986 3/ND/14-30 demyelinated S-M pnp D D ND
[10]/1987 1/ND/29 S-M pnp D D D
[11]/1990 1/ND/30 S-M pnp D D ND
[12]/1991 1/ND/22 Axonal pnp D D ND
[13]/1992 10/ND/26-44 Mixed S-M pnp (2) and
demyelinating S-M pnp (8)
D ND ND
[14]/1995 1/ND/34 Mixed D ND ND
[15]/2000 10/Da/24-54 Axonal pnp (5), mixed pnp (1), pnp
(1)
D D D
[16]/2007 1/Db/47 Polyneuropathy D ND ND
[17]/2007 1/Dc/42 S-M polyneuropathy D D ND
No = number; ND = not determined; D = determined; S-M = sensori-motor; pnp = peripheral neuropathy;
a = mutations on both alleles of the CYP 27 gene in all 10 patients (Table 1 of [15])
b = mutations 1016C > T (T339M) and 1183C > T (R395C) in the CYP21A2 gene
c = mutations 379C > T (R94W) and 1420 C > T (R441W) in the CYP27A1 gene
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complementary testing of several small somatic systems
and ANS. But again, as shown in this study, there is a dis-
crepancy between the finding of IENF density measure-
ment and Q-Sweat test. This mismatch of the inter-lab
data also needs further large scale study for verification. In
this study, IENF density measurement revealed a relatively
high incidence (75%, 3/4) of small fiber involvement in
CTX, and this figure of incidence is as high as those neuro-
pathies with a small-fiber sensory neuropathy [40-43].
Conclusion
Peripheral neuropathy, especially the subtype axonal
sensori-motor neuropathy, is common in patients with
CTX. Evidence of lipid metabolic derangement in CTX
can be reflected in ultrastructural studies of muscles.
With an adequate multi-parametric evaluation, a high
incidence of ANS abnormality can be seen in this
uncommon lipid-storage disease, and a high incidence
of small fiber involvement is also reflected in the IENF
density measurement of skin biopsies. This study is lim-
ited by its small case number, but it may shed light on
further studies of the clinical and laboratory involve-
ments in CTX.
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